TTOO — T2 Biosystems Cashflow Statement
0.000.00%
Last trade - 00:00- $77.91m
- $113.36m
- $7.19m
Annual cashflow statement for T2 Biosystems, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -59 | -46.8 | -49.2 | -62 | -50.1 |
| Depreciation | |||||
| Non-Cash Items | 9.59 | 8.41 | 11.3 | 10.8 | 5.12 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.86 | -6.54 | -2.17 | -0.503 | -4.04 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -45.4 | -43.2 | -38.9 | -50.6 | -48.1 |
| Capital Expenditures | -0.761 | -0.804 | -0.46 | -0.339 | -0.192 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -35.5 | 25.3 | 10 | 0 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.761 | -36.3 | 24.8 | 9.66 | -0.192 |
| Financing Cash Flow Items | 6.65 | 85.3 | — | -0.243 | -0.062 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 6.35 | 85.6 | 20.5 | 29.1 | 52.7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -39.8 | 6.13 | 6.45 | -11.9 | 4.36 |